Phosphodiesterase 4 Inhibitor
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors are a class of drugs that target the enzyme phosphodiesterase 4 (PDE4), which plays a key role in regulating inflammatory responses within the body. By inhibiting PDE4, these drugs increase intracellular levels of cyclic adenosine monophosphate (cAMP), leading to a reduction in the production of pro-inflammatory mediators and an increase in anti-inflammatory mediators. This mechanism of action makes them effective in treating conditions characterized by chronic inflammation.
The first drug in this class, DALIRESP (roflumilast), was approved in 2011 by AstraZeneca for the treatment of chronic obstructive pulmonary disease (COPD) and chronic bronchitis. Since then, the field has seen the development of next-generation agents like EUCRISA (crisaborole) and ZORYVE (roflumilast), which have expanded the therapeutic landscape to include dermatological conditions such as atopic dermatitis and plaque psoriasis. The most recent approval is OHTUVAYRE (ensifentrine) in 2024 for COPD, indicating continued innovation and investment in this therapeutic area.
The future of PDE4 inhibitors appears promising, with ongoing research exploring new indications and patient populations. The development of oral and topical formulations, along with efforts to improve selectivity and reduce side effects, suggests a growing potential for these agents to address a wider range of inflammatory diseases. The recent approval of OTEZLA XR (apremilast) in 2025 for psoriatic arthritis and plaque psoriasis further underscores the expanding reach and clinical utility of this drug class.
7 FDA-approved Phosphodiesterase 4 Inhibitor drugs, including DALIRESP, with 34 active Phase 3 trials across 8 indications from 4 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Phosphodiesterase 4 Inhibitor Drugs
7 totalPhosphodiesterase 4 Inhibitor drugs have evolved significantly since the first-in-class approval of DALIRESP (roflumilast) by AstraZeneca in 2011 for COPD. Initially developed to address inflammatory lung diseases, the class has since expanded its reach into dermatology with agents like EUCRISA (crisaborole) from Anacor Pharmaceuticals, approved in 2016 for atopic dermatitis. More recent innovations include ZORYVE (roflumilast) by Arcutis, approved in 2022 for plaque psoriasis and atopic dermatitis, and OHTUVAYRE (ensifentrine) by Verona Pharma, approved in 2024 for COPD. These newer agents often feature improved selectivity or different delivery methods, aiming for enhanced efficacy and tolerability compared to earlier iterations. Individual Phosphodiesterase 4 Inhibitor drugs differentiate themselves through various factors, including their indication coverage, route of administration, and pharmacokinetic profiles. For instance, roflumilast is available as DALIRESP for COPD and ZORYVE for dermatological conditions, showcasing distinct therapeutic applications. Crisaborole (EUCRISA) is a topical formulation, offering a localized treatment approach for atopic dermatitis, while apremilast (OTEZLA) is an oral medication approved for psoriatic arthritis and plaque psoriasis. OTEZLA XR, a new extended-release formulation, is anticipated in 2025 for similar indications, suggesting a focus on optimizing dosing convenience. Currently, Phosphodiesterase 4 Inhibitors hold established positions in the treatment paradigms for their respective indications. DALIRESP and OHTUVAYRE are used in COPD management, while OTEZLA and ZORYVE are key options for plaque psoriasis and psoriatic arthritis. EUCRISA serves as a topical treatment for atopic dermatitis. The emergence of generic roflumilast in 2018 from Alkem Labs indicates growing market competition. While generally well-tolerated, class-wide gastrointestinal side effects remain a consideration, influencing their positioning, particularly in earlier lines of therapy or in patients with comorbidities.
Phosphodiesterase 4 Inhibitor Indications in Trials
Active industry trialsThe active Phase 2 and 3 pipeline for Phosphodiesterase 4 Inhibitors shows significant activity concentrated in dermatological and respiratory indications. Plaque Psoriasis currently leads with 2 active trials, followed by Chronic Obstructive Pulmonary Disease (COPD) with 1 active trial. Other indications with notable pipeline presence include Active Juvenile Psoriatic Arthritis and Behçet's Disease, each with 1 active trial. This distribution highlights a continued focus on leveraging the anti-inflammatory properties of PDE4 inhibitors for chronic inflammatory conditions, with a strong emphasis on diseases with significant unmet needs or where existing therapies have limitations. Beyond the established approval spaces, the Phosphodiesterase 4 Inhibitor pipeline is exploring expansion into novel patient subpopulations and potentially new disease areas. While specific new indications are not detailed, the presence of trials in Behçet's Disease and Juvenile Psoriatic Arthritis suggests an effort to broaden the therapeutic scope. The development of next-generation agents and potentially combination regimens could further enhance efficacy in refractory patient groups. The current data points to a pipeline dominated by oral formulations, aligning with the established routes of administration for many approved PDE4 inhibitors. Looking ahead to the next 6-12 months, key readouts from ongoing Phase 2 and 3 trials in Plaque Psoriasis and COPD will be critical for assessing the near-term trajectory of the Phosphodiesterase 4 Inhibitor class. The presence of active trials in Behçet's Disease and Juvenile Psoriatic Arthritis suggests these areas are potential growth frontiers. However, the overall number of active Phase 2/3 trials (9 total) indicates a moderately active but not explosive pipeline. Signals to watch include the success rates in these emerging indications and any indications where the class has historically struggled, which could reveal bottlenecks or areas ripe for innovation.
Top Phosphodiesterase 4 Inhibitor Sponsors
Industry trials, any indicationAmgen stands out as the dominant player in the active Phase 2 and 3 Phosphodiesterase 4 Inhibitor trial landscape, leading with 5 active trials. This leadership is likely driven by their established franchise with OTEZLA and the upcoming OTEZLA XR, indicating a deep commitment to leveraging apremilast across multiple indications, including psoriatic arthritis and plaque psoriasis. Their substantial trial count suggests a strategic focus on expanding the reach and utility of their PDE4 inhibitor assets. Verona Pharma plc is a key challenger, actively pursuing the COPD indication with 1 active trial, likely related to their recently approved OHTUVAYRE. Bristol-Myers Squibb also maintains a presence with 1 active trial, potentially building on their experience with OTEZLA. SFA Therapeutics is another sponsor with 1 active trial, indicating emerging competition or exploration in new therapeutic areas within the PDE4 inhibitor space. These sponsors are actively contributing to the ongoing development and potential expansion of the class. The strategic landscape for Phosphodiesterase 4 Inhibitors appears largely centered on established pharmaceutical companies with existing portfolios in inflammatory diseases. Amgen's strong presence suggests a focus on maximizing their current assets, while Verona Pharma's recent approval and ongoing trials highlight a dedicated effort in respiratory indications. The presence of generic manufacturers, such as Alkem Labs for roflumilast, indicates a maturing market for older agents. Upcoming catalysts will likely revolve around pivotal trial readouts and potential new approvals, which could shift the competitive balance and present strategic opportunities for investors and business development scouts.
Phosphodiesterase 4 Inhibitor Phase 3 Readout Calendar Pro
11 Phase 3 trials testing approved Phosphodiesterase 4 Inhibitor drugs across 5 indications from 4 sponsors. Earliest readout: Q4 2024.
Coverage: trials whose intervention is an approved Phosphodiesterase 4 Inhibitor drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.